Masahiro Tsuboi, MD, National Cancer Center Hospital East

home / authors / masahiro-tsuboi-md-national-cancer-center-hospital-east

Articles

Masahiro Tsuboi, MD

Dr Tsuboi on Updated Survival Results of the ADAURA Trial in Resectable NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East
July 29th 2023

Masahiro Tsuboi, MD, discusses the updated survival results of the phase 3 ADAURA trial in resectable EGFR-mutant non–small cell lung cancer.

Read More

Masahiro Tsuboi, MD

Dr. Tsuboi on Findings From the Phase 3 ADAURA Trial in EGFR+ NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East
November 20th 2020

Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses findings from the phase 3 ADAURA trial in EGFR-mutant non–small cell lung cancer.

Read More

Paradigm Shift for Early EGFR+ NSCLC

Paradigm Shift for Early EGFR+ NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More

Practical Implications of ADAURA in NSCLC

Practical Implications of ADAURA in NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More

Unprecedented Results from ADAURA

Unprecedented Results from ADAURA

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More

Adjuvant Approaches in EGFR+ NSCLC

Adjuvant Approaches in EGFR+ NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More

Standard of Care for EGFR+ ES-NSCLC

Standard of Care for EGFR+ ES-NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More

Testing for EGFR in NSCLC Worldwide

Testing for EGFR in NSCLC Worldwide

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More

Molecular Testing in Early-Stage NSCLC

Molecular Testing in Early-Stage NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More

Determining Resectability in ES-NSCLC

Determining Resectability in ES-NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More

Clinical Evaluation of ES-NSCLC in Japan

Clinical Evaluation of ES-NSCLC in Japan

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More